"But, in the submission to the FDA the comparison becomes important in presenting non-inferiority or superiority over the current standard treatment."
Can I infer that....not addressing B but generally....the FDA would not approve a drug that is effective, but less so, than an existing drug? If that's true, and I'm a little bit afraid to ask, but do they also take price into consideration?